A STATement on Vemurafenib-Resistant Melanoma

Despite recent advancements in the treatment of late-stage mutant BRAF (V600E/K) melanomas, a major hurdle continues to be acquired resistance to BRAF inhibitors such as Vemurafenib. The mechanisms for resistance have proven to be heterogeneous, emphasizing the need to utilize broad therapeutic appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartsough, Edward J., Aplin, Andrew E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3713534/
https://www.ncbi.nlm.nih.gov/pubmed/23856932
http://dx.doi.org/10.1038/jid.2013.136
_version_ 1782277202611535872
author Hartsough, Edward J.
Aplin, Andrew E.
author_facet Hartsough, Edward J.
Aplin, Andrew E.
author_sort Hartsough, Edward J.
collection PubMed
description Despite recent advancements in the treatment of late-stage mutant BRAF (V600E/K) melanomas, a major hurdle continues to be acquired resistance to BRAF inhibitors such as Vemurafenib. The mechanisms for resistance have proven to be heterogeneous, emphasizing the need to utilize broad therapeutic approachs. The present study, “Stat3 targeted therapies overcome the acquired resistance to vemurafenib in melanomas” by Liu et al., proposes that STAT3-PAX3 signaling may be a mechanism that is utilized by melanomas to resist RAF inhibitors.
format Online
Article
Text
id pubmed-3713534
institution National Center for Biotechnology Information
language English
publishDate 2013
record_format MEDLINE/PubMed
spelling pubmed-37135342014-02-01 A STATement on Vemurafenib-Resistant Melanoma Hartsough, Edward J. Aplin, Andrew E. J Invest Dermatol Article Despite recent advancements in the treatment of late-stage mutant BRAF (V600E/K) melanomas, a major hurdle continues to be acquired resistance to BRAF inhibitors such as Vemurafenib. The mechanisms for resistance have proven to be heterogeneous, emphasizing the need to utilize broad therapeutic approachs. The present study, “Stat3 targeted therapies overcome the acquired resistance to vemurafenib in melanomas” by Liu et al., proposes that STAT3-PAX3 signaling may be a mechanism that is utilized by melanomas to resist RAF inhibitors. 2013-08 /pmc/articles/PMC3713534/ /pubmed/23856932 http://dx.doi.org/10.1038/jid.2013.136 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Hartsough, Edward J.
Aplin, Andrew E.
A STATement on Vemurafenib-Resistant Melanoma
title A STATement on Vemurafenib-Resistant Melanoma
title_full A STATement on Vemurafenib-Resistant Melanoma
title_fullStr A STATement on Vemurafenib-Resistant Melanoma
title_full_unstemmed A STATement on Vemurafenib-Resistant Melanoma
title_short A STATement on Vemurafenib-Resistant Melanoma
title_sort statement on vemurafenib-resistant melanoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3713534/
https://www.ncbi.nlm.nih.gov/pubmed/23856932
http://dx.doi.org/10.1038/jid.2013.136
work_keys_str_mv AT hartsoughedwardj astatementonvemurafenibresistantmelanoma
AT aplinandrewe astatementonvemurafenibresistantmelanoma
AT hartsoughedwardj statementonvemurafenibresistantmelanoma
AT aplinandrewe statementonvemurafenibresistantmelanoma

Ejemplares similares